When the National Institutes of Health (NIH) announced in July that it would move forward with a Biden-era proposal to require “access plans” for companies seeking to license NIH-owned patents, the decision stunned many in the innovation community. Industry groups warned that this new bureaucratic hurdle would “kill NIH licensing.” They’re right, and not merely ... The NIH ‘Access Plan’ Mandate: Central Planning by Another Name The post The NIH ‘Access Plan’ Mandate: Central...
